In an interview with Pharmacy Times®, Ryan Haumschild, PharmD, MS, MBA director of pharmacy at Emory Healthcare and Winship Cancer Institute, discusses the pharmacists role in care teams for targeted therapies at the Academy of Managed Care Pharmacy Annual Meeting.
In an interview with Pharmacy Times®, Chelsee Jensen, PharmD, pharmaceutical formulary manager at Mayo Clinic, discusses biosimilar usage in health systems and challenges that come with it.
Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the barriers patients with cancer may experience that oncology pharmacists can help them navigate through.
During this round, students were allowed to collaborate with their teammates to come up with the answers, and they wagered their points with each question.
Melissa Johnson, MD, program director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses her presentation at the Community Oncology Alliance 2022 conference on new drugs in the non-small cell lung cancer space.
Jim Schwartz, RPh, executive director of pharmacy operations for Oncology Pharmacy Services, discusses his presentation at the Community Oncology Alliance 2022 conference on the new world of oral cancer drug dispensing.
In an interview with Pharmacy Times®, Eric Tichy, PharmD, MBA, BCPS, FAST, FCCP, Vice Chair of Pharmacy/Formulary at Mayo Clinic, discusses some formulary trends in biosimilars at the Academy of Managed Care Pharmacy Annual Meeting.
Lumateperone (Caplyta) is used for the treatment of schizophrenia and bipolar depression.
Fremanezumab-vfrm is the second FDA-approved preventive migraine treatment that works by blocking the activity of calcitonin gene-related peptide.
With therapeutics developing quickly in the cardiovascular space, pharmacists are more important than ever.
Pharmacy Times spoke with Dave Dixon, PharmD, to learn more about his presentation titled “New Pharmacologic Therapies for Heart Failure.
George MacKinnon, PhD, MS, RPh, FASHP, FNAP, discussed how a multi-pronged approach to burnout is necessary in the pharmacy environment.
Mark Svet, MD, is the lead study author on a sub-analysis of the VOYAGER PAD study evaluating data on the use of rivaroxaban in patients with peripheral artery disease (PAD) and chronic kidney disease (CKD).
Pharmacy Times spoke with Dipti Itchhaporia, MD, the 70th president of the American College of Cardiology (ACC).
Pharmacy Times spoke with Craig Granowitz, MD, PhD, chief medical officer at Lexicon Pharmaceuticals, to learn more about sotagliflozin and new data being presented at the American College of Cardiology 2022 Scientific Sessions.
Pharmacy Times spoke with Orly Vardeny, PharmD, MS, a core investigator at the Center for Care Delivery and Outcomes Research in the US Department of Veterans Affairs, about pharmacists’ roles in managing pharmacotherapy disparities.
Milind Desai, MD, national principal investigator of the VALOR-HCM trial, discussed new results presented at the American College of Cardiology 2022 Scientific Sessions.
Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the barriers that patients with cancer may encounter following their diagnosis.
George MacKinnon, founding dean of the Medical College of Wisconsin School of Pharmacy and a professor there, discusses burnout in the pharmacy and how it can ultimately impact patients.
In part 2 of the Pharmacy Times® Pharmacy Face-Off Gameshow™, pharmacy students from the University of the Sciences Philadelphia College of Pharmacy and the Rutgers University Ernest Mario School of Pharmacy entered a lightning round with clinical questions.
A panel of experts discuss the role of PrEP in HIV prevention with a focus on current and newly approved options.
Ted Okon, MBA, executive director of the Community Oncology Alliance (COA), discusses key highlights from the in-person COA 2022 conference.
Christy S. Harris, PharmD, BCOP, FHOPA, clinical pharmacy specialist at Dana-Farber Cancer Institute, discusses guidelines for common therapies and appropriate monitoring recommendations for selected therapies used in the treatment of adult sarcomas.
Vimala Raghavendran, MBA, head of the Pharmaceutical Supply Chain Center at US Pharmacopeia (USP), explains how pharmacists can get involved in USP’s Medicine Supply Vulnerability Insights Series assessing global pharmaceutical supply chain vulnerabilities.
Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), discusses ways to address burnout in the hematology/oncology space.
Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), provides details of the upcoming HOPA 2022 conference.
Elizabeth Spurlock, MA, PHR, director of HR Business Partner at Texas Oncology, discusses how burnout among physicians, nurses, and hospital administrators has impacted the role of the pharmacist in patient care.
Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), provides details of the upcoming HOPA 2022 conference.
Pharmacy Times spoke with students at the Idaho State University College of Pharmacy and its partner program at the University of Alaska Anchorage College of Health.
Lisa Nodzon, PhD, ARNP, AOCNP; Katie Tobon, PharmD, BCOP; and Javier Pinilla-Ibarz, MD, PhD, share insight on strategies for the monitoring and management of BTK inhibitor–associated toxicities in CLL and review the importance of a multidisciplinary approach to treatment.
